Law firms are urging investors to join a securities class action lawsuit against Capricor Therapeutics. The lead plaintiff filing deadline is September 28, 2026. This action covers investors who purchased securities between December 17, 2025, and July 26, 2026.
The lawsuit alleges that Capricor and its executives issued misleading statements regarding its lead product candidate, Deramiocel. It claims the company failed to disclose unapproved changes to the statistical analysis plan for clinical data. These undisclosed changes reportedly created significant risks for FDA regulatory approval.
The FDA published briefing documents in late July 2026 that questioned the drug's effectiveness. Regulators noted an unfavorable benefit-risk profile for Deramiocel. Capricor's stock price fell 64% on July 27, 2026.